Banyan Capital Management Inc. Sells 24,712 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Banyan Capital Management Inc. decreased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 19.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 102,722 shares of the company’s stock after selling 24,712 shares during the period. Henry Schein makes up 4.3% of Banyan Capital Management Inc.’s holdings, making the stock its 12th largest position. Banyan Capital Management Inc. owned 0.08% of Henry Schein worth $7,108,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ING Groep NV acquired a new stake in shares of Henry Schein in the 3rd quarter valued at approximately $63,226,000. Holocene Advisors LP acquired a new stake in Henry Schein in the third quarter worth $58,319,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Henry Schein during the third quarter worth $43,740,000. Southpoint Capital Advisors LP grew its holdings in shares of Henry Schein by 30.0% in the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after buying an additional 600,000 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Henry Schein by 365.6% in the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after buying an additional 558,689 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HSIC. Mizuho started coverage on Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 target price for the company. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Barrington Research increased their target price on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, January 30th. Jefferies Financial Group lifted their price target on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Finally, Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Henry Schein presently has a consensus rating of “Moderate Buy” and an average price target of $80.09.

Henry Schein Stock Performance

HSIC opened at $77.83 on Thursday. The business’s 50-day simple moving average is $74.11 and its 200 day simple moving average is $72.11. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The firm has a market capitalization of $9.70 billion, a PE ratio of 32.03, a PEG ratio of 2.15 and a beta of 0.91.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.